Posted on August 9th, 2022 by Ann-Marie Roche in Pharma R&D
competitive in R&D, it is critical to keep abreast of all the latest
findings and innovations. Preprints are offering a new way to remain ahead of
the curve, allowing a look into new research prior to the peer-review process.
early versions of scholarly papers that are made available on public preprint
servers in advance of publication. Because they have not gone through peer
review, they must be approached with some caution. But as long as this is
understood, they can be a highly valuable resource for the latest research,
including, for example, randomized controlled trials.
Elsevier’s biomedical database Embase just began offering preprints earlier this year, providing users with access to article preprints from two major sites. One is medRXiv, the health sciences preprint server created by Cold Spring Harbor Laboratory (CSHL), Yale University, and BMJ. The other is bioRXiv, the preprint server for biology, which is also operated by CSHL.
One of the
advantages of preprints is not only that they can offer a window into
up-to-the-minute research and findings, but that they can generate constructive
feedback around the research that they present. This is especially important
given that, as mentioned, these papers haven’t been peer-reviewed yet. The
public response on online platforms, including in the comment sections of the
preprint servers themselves, can help readers get vital context and a better
understanding of the subject at hand.
Recently, members of the ASAPbio preprint review cultural norms Working Group shared their advice for how to make preprint feedback constructive in the form of principles that they call the FAST Principles for preprint feedback. The principles, which are clustered around the broad themes of Focused, Appropriate, Specific and Transparent, are designed to guide responsible discourse around preprints.
“At this early
stage,” they wrote, “we all have an opportunity to contribute to positive
change, as we move towards the culture of preprint feedback we’d like to see.”
R&D Solutions for Pharma & Life Sciences
We’re happy to discuss your needs and show you how Elsevier’s Solution can help.